EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy of anti‐ IL‐23 and anti‐ IL‐17 after adalimumab failure in psoriatic patients

L Mastorino iD, S Susca, C Cariti, N Sliquini iD, A Verrone, E Stroppiana, M Ortoncelli, P Dapavo, S Ribero iD, P Quaglino iD

Journal of the European Academy of Dermatology and Venereology · 2023-09 · 37 (9) · 1848-1853

DOI: 10.1111/jdv.19135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 04.05.2023. Verfasst von L Mastorino und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Psoriasis. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Many national guidelines at the European level recommend first‐line therapy based on the anti‐TNF‐alpha adalimumab for treatment of psoriasis and psoriatic arthritis, mainly for economic reasons. Consequently, patients being treated with newer IL‐17 and IL‐23 inhibitors underwent previous unsuccessful first‐line adalimumab‐based therapy.

Objectives

Evaluate the efficacy and safety of IL‐17 and IL‐23 inhibitors after treatment with adalimumab compared to adalimumab‐naive psoriatic patients.

Methods

We retrospectively analysed 1053 psoriatic patients treated with anti‐IL17 and anti‐IL23 agents, which included 68 and 24 adalimumab‐experienced and 399 and 260 bio‐naive patients. Efficacy was assessed with mean PASI, PASI90, PASI100, and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticPsoriasisHumansAdalimumabRetrospective StudiesSeverity of Illness IndexTreatment OutcomeTumor Necrosis Factor InhibitorsInterleukin-23Interleukin-17

Substanzen

AdalimumabTumor Necrosis Factor InhibitorsInterleukin-23Interleukin-17

Autor:innen und Institutionen

  • Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy.

ORCID-Profile: L Mastorino, N Sliquini, S Ribero, P Quaglino

Zitieren

APA

Mastorino, L., Susca, S., Cariti, C., Sliquini, N., Verrone, A., Stroppiana, E., Ortoncelli, M., Dapavo, P., Ribero, S., & Quaglino, P. (2023). Efficacy of anti‐ IL‐23 and anti‐ IL‐17 after adalimumab failure in psoriatic patients. Journal of the European Academy of Dermatology and Venereology, 37(9), 1848-1853. https://doi.org/10.1111/jdv.19135

Vancouver

Mastorino L, Susca S, Cariti C, Sliquini N, Verrone A, Stroppiana E, et al. Efficacy of anti‐ IL‐23 and anti‐ IL‐17 after adalimumab failure in psoriatic patients. Journal of the European Academy of Dermatology and Venereology. 2023;37(9):1848-1853. doi:10.1111/jdv.19135

BibTeX
@article{Mastorino2023,
  author = {Mastorino, L and Susca, S and Cariti, C and Sliquini, N and Verrone, A and Stroppiana, E and Ortoncelli, M and Dapavo, P and Ribero, S and Quaglino, P},
  title = {Efficacy of anti‐ IL‐23 and anti‐ IL‐17 after adalimumab failure in psoriatic patients},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  volume = {37},
  number = {9},
  pages = {1848--1853},
  doi = {10.1111/jdv.19135}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche